Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon AdenocarcinomaSalomé Paillas(Inserm), Céline Gongora(Institut de Recherche en Cancérologie de Montpellier)Cancer ResearchDecember 15, 201010.1158/0008-5472.can-10-2726Cited by 87SaveCiteExport RISWatch citationsRelated PapersFOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer|British Journal of Cancer|2016|51